Vanguard Investments Australia
XERS icon

Vanguard Investments Australia’s Xeris Biopharma Holdings XERS Stock Holding History

Vanguard Investments Australia’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318K Hold
40,202
– – ﹤0.01% 1900
2026
Q1 		$233K Buy
+40,202
New +$267K ﹤0.01% 1965

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Investments Australia's XERS Position: Q2 2026 in Review

Vanguard Investments Australia held its Xeris Biopharma Holdings (XERS) position steady in Q2 2026 at 40,202 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #1900.

Vanguard Investments Australia first reported a position in XERS in Q1 2026 and has held it in 2 quarters since. 239 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Vanguard Investments Australia held 40,202 shares of Xeris Biopharma Holdings worth $318K as of Q2 2026.
  • Vanguard Investments Australia left its Xeris Biopharma Holdings share count unchanged in Q2 2026.
  • Xeris Biopharma Holdings made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1900 holding.
  • Vanguard Investments Australia first reported a position in Xeris Biopharma Holdings in Q1 2026 and has held it in 2 quarters since.
  • 239 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.